Shattuck is a biotechnology company developing a potentially first-in-class antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and commitment to pursuing the development of novel therapeutics targeting TNF receptors come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve complete and more durable blockade of the clinically validated TL1A/DR3 pathway. Shattuck intends to file an Investigational New Drug application (IND) for SL-325 in the third quarter of 2025.